Table 1.
Results of re-analysis of the Bar-Sela correction [9], with total N = 102, evaluating potential adverse effects of cannabis on immunotherapy using C chi-square, F Fisher’s, or Y Yates non-parametric statistics. Minimum expected cell N determined in [26]. The British Medical Journal (BMJ) guidance on the recommend non-parametric statistic is reported [20]. atezo: atezolizumab, COPD: chronic obstructive pulmonary disease, ECOG: Eastern Cooperative Oncology Group, LC: lung cancer, nivo: nivolumab.
| Variable | Smallest Cell N Observed (Expected) |
BMJ Statistic | Reported p | Calculated p | Interpretation |
|---|---|---|---|---|---|
| Gender | 10 (10.67) | chi-square | 0.9399 C or F | 0.9399 Y | Misreported |
| ECOG | 10 (7.67) | chi-square | 0.3568 C or F | 0.3568 Y | Misreported |
| Chronic diseases = 0 Chronic diseases = 1 Chronic diseases = 2+ |
13 (11.67) 7 (7.67) 14 (14.67) |
chi-square chi-square chi-square |
0.7124 C or F 0.9332 C or F 0.9437 C or F |
0.7124 Y 0.9332 Y 0.9437 Y |
Misreported Misreported Misreported |
| Chronic heart disease | 5 (7.67) | chi-square | 0.2762 C or F | 0.2762 Y | Misreported |
| Diabetes | 6 (7.67) | chi-square | 0.5576 C or F | 0.5576 Y | Misreported |
| High blood pressure | 13 (15.67) | chi-square | 0.3612 C or F | 0.3612 Y | Misreported |
| COPD | 3 (4.00) | chi-square | 1 C or F | 0.5145 C, 0.7463 F, 0.7445 Y | Unverified |
| Hyperlipidemia | 7 (10.00) | chi-square | 0.2491 C or F | 0.2491 Y | Misreported |
| Other disease | 0 (-) | chi-square | 1 C or F | 0.3125 C, 0.5512 F, 0.8007 Y | Unverified |
| Non-small-cell LC | 14 (15.00) | chi-square | 0.8325 C or F | 0.8325 Y | Misreported |
| Melanoma | 9 (11.33) | chi-square | 0.414 C or F | 0.4140 Y | Misreported |
| Renal cell carcinoma | 2 (2.00) | chi-square | 1 C or F | 1.000 C,F,Y | Verified |
| Other malignancy | 3 (1.67) | chi-square | 1 C or F | 0.1946 C, 0.3300 F, 0.4175 Y | Unverified |
| Brain metastasis | 8 (6.67) | chi-square | 0.6593 C or F | 0.6593 Y | Misreported |
| Lungs metastasis | 11 (13.33) | chi-square | 0.4303 C or F | 0.4303 Y | Misreported |
| Liver metastasis | 11 (8.00) | chi-square | 0.2157 C or F | 0.2157 Y | Misreported |
| Immunotherapy 1st line | 8 (13.00) | chi-square | 0.05178 C or F | 0.0518 Y | Misreported |
| Pembrolizumab or nivo | 5 (8.67) | chi-square | 0.127 C or F | 0.1270 Y | Misreported |
| Ipilimumab and nivo | 4 (6.67) | chi-square | 0.2517 C or F | 0.2517 Y | Misreported |
| Durvalumab or atezo | 1 (2.00) | chi-square | 1 C or F | 0.3720 C, 0.6607 F, 0.6554 Y | Unverified |